Sentence examples for presentation presence from inspiring English sources

Factors analysed included patient (age group, gender, performance status (BS) at diagnosis of metastases), disease (number of metastatic sites, specific metastatic sites, disease-free interval (DFI), metastases at presentation, presence of locoregional recurrence), and laboratory factors (leucocyte count, haemoglobin level, albumin level).

Our analyses of hemostasis and inflammatory markers were not affected by time between the onset of symptoms of pneumonia and ED presentation, presence or absence of severe sepsis, or in subjects with PCT≥0.25.

We recorded age, clinical presentation, presence or absence of a documented immunisation history and any details of immunisation recorded.

Data were collected on tumour stage at presentation, presence and sites of metastatic disease, tumour pathology, survival and results of routine laboratory tests.

Data were collected on tumour stage at presentation, presence and sites of metastatic disease, tumour pathology and results of routine laboratory tests.

The proximal subtype was significantly correlated with a proximal tumor location, distant metastases at presentation, presence of rhabdoid cells, a higher tumor grade, and vascular invasion.

Despite of heterogeneity of FM in its clinical presentations, presence of TTH must be assessed.

We compared the prognostic accuracy of OAC with other commonly used prognostic markers and scores: BISAP score [15], C-reactive protein at 48 h from presentation [16], presence of SIRS criteria at emergency room and presence of persistent SIRS (> 48 h) [17, 18] and hematocrit at emergency room higher than 44%[19]].

Patient factors associated with transfer to private rather than VHA tertiary hospital included elevated ST-segment on presenting electrocardiogram, abnormal cardiac enzymes on presentation, and presence of a do not resuscitate order during the hospitalization.

The diagnosis of VL at the time of the self-resolving episode was strongly suspected based on clinical presentation and presence of antileishmanial antibody, then unequivocally confirmed years later by the presence of an amastigote on a stored smear.

For the within-cohort analysis of association with disease severity, a number of measures were assessed reflecting disease activity (CRP at baseline, swollen joint count at baseline and at 5 years following presentation), severity (presence of erosions by 1 and 5 years, Larsen score by 1 and 5 years, presence of anti-CCP antibodies and RF at baseline) and disability (HAQ score).